Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial

William Wilson Kemp; John Colman; Kenneth Thompson; Anoop Madan; Margaret Vincent; Jaye PF Chin-Dusting; Andrew Richard Kompa; Henry Krum; Stuart Roberts

doi:10.1111/j.1478-3231.2008.01850.x

Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial

William Wilson Kemp, John Colman, Kenneth Thompson, Anoop Madan, Margaret Vincent, Jaye PF Chin-Dusting, Andrew Richard Kompa, Henry Krum, Stuart Roberts

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

29 Citations (Scopus)

Abstract

While selective intestinal decontamination (SID) can alter the hyperdynamic circulatory state of cirrhosis, the impact of SID on portal pressure remains unclear especially in the setting of clinically significant portal hypertension. Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects

Original language	English
Pages (from-to)	427 - 433
Number of pages	7
Journal	Liver International
Volume	29
Issue number	3
DOIs	https://doi.org/10.1111/j.1478-3231.2008.01850.x
Publication status	Published - 2009

Access to Document

10.1111/j.1478-3231.2008.01850.x

Cite this

Kemp, William Wilson ; Colman, John ; Thompson, Kenneth ; Madan, Anoop ; Vincent, Margaret ; Chin-Dusting, Jaye PF ; Kompa, Andrew Richard ; Krum, Henry ; Roberts, Stuart. / Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. In: Liver International. 2009 ; Vol. 29, No. 3. pp. 427 - 433.

@article{1c44022aecca48398149cd3fcae4a742,

title = "Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial",

abstract = "While selective intestinal decontamination (SID) can alter the hyperdynamic circulatory state of cirrhosis, the impact of SID on portal pressure remains unclear especially in the setting of clinically significant portal hypertension. Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects",

author = "Kemp, {William Wilson} and John Colman and Kenneth Thompson and Anoop Madan and Margaret Vincent and Chin-Dusting, {Jaye PF} and Kompa, {Andrew Richard} and Henry Krum and Stuart Roberts",

year = "2009",

doi = "10.1111/j.1478-3231.2008.01850.x",

language = "English",

volume = "29",

pages = "427 -- 433",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell",

number = "3",

}

Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. / Kemp, William Wilson; Colman, John; Thompson, Kenneth; Madan, Anoop; Vincent, Margaret; Chin-Dusting, Jaye PF; Kompa, Andrew Richard; Krum, Henry; Roberts, Stuart.

In: Liver International, Vol. 29, No. 3, 2009, p. 427 - 433.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial

AU - Kemp, William Wilson

AU - Colman, John

AU - Thompson, Kenneth

AU - Madan, Anoop

AU - Vincent, Margaret

AU - Chin-Dusting, Jaye PF

AU - Kompa, Andrew Richard

AU - Krum, Henry

AU - Roberts, Stuart

PY - 2009

Y1 - 2009

N2 - While selective intestinal decontamination (SID) can alter the hyperdynamic circulatory state of cirrhosis, the impact of SID on portal pressure remains unclear especially in the setting of clinically significant portal hypertension. Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects

AB - While selective intestinal decontamination (SID) can alter the hyperdynamic circulatory state of cirrhosis, the impact of SID on portal pressure remains unclear especially in the setting of clinically significant portal hypertension. Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects

UR - http://www.ingentaconnect.com/content/mksg/liv/2009/00000029/00000003/art00018

U2 - 10.1111/j.1478-3231.2008.01850.x

DO - 10.1111/j.1478-3231.2008.01850.x

M3 - Article

VL - 29

SP - 427

EP - 433

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 3

ER -

Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial

Abstract

Access to Document

Other files and links

Cite this